Group C Meningococcal Vaccine Trial: Safety, Immunogenicity and Parents’ Views of Participation
Intended for healthcare professionals
A&S Science Previous     Next

Group C Meningococcal Vaccine Trial: Safety, Immunogenicity and Parents’ Views of Participation

Caroline Jonas Paediatric Research Nurse, Oxford Vaccine Group

In 1995, the Oxford Vaccine Group evaluated the safety and immunogenicity of a Group C meningococcal conjugate vaccine in 182 infants using the UK vaccination schedule*. During and after the study we sought the views of parents about the vaccine and about their participation in the trial. The vaccine was well tolerated and resulted in fewer local reactions than the routine vaccinations, with no increase in systemic reactions. Post-vaccination antibody levels increased progressively after each dose of conjugate vaccine. We concluded that this meningococcal C conjugate vaccine is safe and immunogenic. The research process and the views of parents provide important lessons for researchers undertaking trials on infants.

*A full report of this study was published in the Journal of the American Medical Association (2000) 283, 21, 2795-2801.

Nursing Children and Young People. 13, 1, 23-26. doi: 10.7748/paed2001.02.13.1.23.c720

Want to read more?

RCNi-Plus
Already have access? Log in

or

3-month trial offer for £5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics
Subscribe

Alternatively, you can purchase access to this article for the next seven days. Buy now


Are you a student? Our student subscription has content especially for you.
Find out more